Abstract
Objective The aim of this cross-sectional single center study was to investigate 18kDa translocator protein (TSPO)-PET as a biomarker for microglial activation in the 4-repeat tauopathies corticobasal degeneration and progressive supranuclear palsy (PSP).
Methods Specific binding of the TSPO tracer 18F-GE-180 was determined by serial PET during pharmacological depletion of microglia in a 4-repeat tau mouse model. TSPO-PET was performed in 30 patients with corticobasal syndrome (CBS, 68±9 years, 16 female) and 14 patients with PSP (69±9 years, 8 female), and 13 control subjects (70±7 years, 7 female). Group comparisons and associations with parameters of disease progression and sTREM2 were assessed by region-based and voxel-wise analyses.
Results Tracer binding was significantly reduced after pharmacological depletion of microglia in 4-repeat tau mice. Elevated TSPO labeling (standardized-uptake-value-ratios) was observed in subcortical brain areas of CBS and PSP patients when compared to controls, most pronounced in the globus pallidus internus (CBS: 1.039 [95%CI 1.000–1.078, p<0.001], PSP: 1.046 [95%CI: 0.990–1.101, p<0.001], controls: 0.861 [95%CI 0.802–0.921]), whereas only CBS patients showed additionally elevated tracer binding in motor and supplemental motor areas. TSPO labeling was only correlated weakly with parameters of disease progression in CBS and PSP but allowed sensitive detection of 4-repeat tauopathy patients. sTREM2 did not differ between patients with CBS and controls.
Interpretation Our data indicate a potential of 18F-GE-180 PET to detect microglial activation in the brain of 4-repeat tauopathy patients, fitting to predilection sites of the phenotype. TSPO-PET may serve as a sensitive early disease stage biomarker in 4-repeat tauopathies.
Competing Interest Statement
M.B. received speaker honoraria from GE healthcare and LMI and is an advisor of LMI. G.U.H. received research support from GE Healthcare and Neuropore; has ongoing research collaborations with Orion and Prothena; serves as a consultant for AbbVie, AlzProtect, Asceneuron, Biogen, Biohaven, Lundbeck, Novartis, Roche, Sanofi, UCB; received honoraria for scientific presentations from AbbVie, Biogen, Roche, Teva, UCB, and Zambon; and holds a patent on PERK Activation for the Treatment of Neurodegenerative Diseases (PCT/EP2015/068734). C.H. is chief scientific advisor of ISAR biosciences and collaborates with DENALI therapeutics. R.P. is on the advisory board for Biogen, has consulted for Eli Lilly, is a grant recipient from Janssen Pharmaceutica and Boehringer Ingelheim, and has received speaker honoraria from Janssen-Cilag, Pfizer and Biogen. J.L. reports speaker fees from Bayer Vital, consulting fees from Axon Neuroscience, author fees from Thieme medical publishers and W. Kohlhammer GmbH medical publishers, non-financial support from Abbvie and compensation for duty as part-time CMO from MODAG GmbH, all outside the submitted work. All other authors do not report a conflict of interest.
Funding Statement
This work was funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) to P.B. and N.A. project number 421887978, to C.W. project number DFG WE2298/10-1, 422182557, and to A.R. and M.B. project numbers BR4580/1-1/ RO5194/1-1. This project was also supported by the German Center for Neurodegenerative Diseases (DZNE, DescribePSP Study), the German Parkinsons Association (DPG, ProPSP Study) and the Hirnliga e.V. (Manfred-Strohscheer-Stiftung). P.B., G.U.H., C.H., J.H. and R.P. were supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germanys Excellence Strategy within the framework of the Munich Cluster for Systems Neurology (EXC 2145 SyNergy ID 390857198). G.U.H. was also funded by the NOMIS foundation (FTLD project). The Lueneburg Heritage has supported the work of C.P.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Human PET data analyses (ethics-applications: 17-569 & 19-022) were approved by the local institutional ethics committee (Ethics committee of the medical faculty, Ludwig-Maximilians-University, Munich, Germany). All participants provided written informed consent according to the Declaration of Helsinki. All animal experiments were performed in compliance with the National Guidelines for Animal Protection, Germany and with the approval of the regional animal committee (Regierung von Oberbayern) overseen by a veterinarian.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data of this manuscript is available from the corresponding author upon reasonable request.
